Transgenic mouse models of Alzheimer's disease: how useful have they been for therapeutic development?

Transgenic mice have been created in an attempt to generate models of human Alzheimer's disease, but success has been partial and unpredictable. The overall aim of this paper is to illustrate how genomics can be used in translational research, turning genetic information in the form of pathogenic mutations into clinically useful drugs against a major human disease. This paper will illustrate how genetic information allows researchers to dissect the aetiology of a disease and then replicate the disease in vivo through the process of transgenesis. The limitations of recreating a condition like Alzheimer's disease in a transgenic mouse, how far the mice have advanced understanding of the disease and how useful they have been for the development of therapeutics will then be discussed.

[1]  J. Trojanowski,et al.  Early Vitamin E supplementation in young but not aged mice reduces Aβ levels and amyloid deposition in a transgenic model of Alzheimer's disease , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[2]  K. Duff,et al.  Use of in Vivo Models to Study the Role of Cholesterol in the Etiology of Alzheimer's Disease , 2003, Neurochemical Research.

[3]  B. Ibach,et al.  Acetylcholinesterase inhibition in Alzheimer's Disease. , 2004, Current pharmaceutical design.

[4]  H. Braak,et al.  Alzheimer's disease affects limbic nuclei of the thalamus , 2004, Acta Neuropathologica.

[5]  R. Stackman,et al.  Prevention of age-related spatial memory deficits in a transgenic mouse model of Alzheimer's disease by chronic Ginkgo biloba treatment , 2003, Experimental Neurology.

[6]  D. Holtzman,et al.  Evidence for peripheral clearance of cerebral Aβ protein following chronic, active Aβ immunization in PSAPP mice , 2003, Neurobiology of Disease.

[7]  D. Dickson,et al.  Amyloid-β Immunization Effectively Reduces Amyloid Deposition in FcRγ-/- Knock-Out Mice , 2003, The Journal of Neuroscience.

[8]  G. Plant,et al.  Cerebral Amyloid Angiopathies: A Pathologic, Biochemical, and Genetic View , 2003, Journal of neuropathology and experimental neurology.

[9]  D. Coulter,et al.  Clioquinol effects on tissue chelatable zinc in mice , 2003, Journal of Molecular Medicine.

[10]  Pritam Das,et al.  NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo , 2003 .

[11]  P. Davies,et al.  Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms , 2003, Journal of neurochemistry.

[12]  M. Mattson,et al.  Triple-Transgenic Model of Alzheimer's Disease with Plaques and Tangles Intracellular Aβ and Synaptic Dysfunction , 2003, Neuron.

[13]  Koji Abe,et al.  Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease , 2003, Journal of neurochemistry.

[14]  B. Shukitt-Hale,et al.  Blueberry Supplementation Enhances Signaling and Prevents Behavioral Deficits in an Alzheimer Disease Model , 2003, Nutritional neuroscience.

[15]  M. Wolfe.  Gamma-secretase--intramembrane protease with a complex. , 2003, Science of aging knowledge environment : SAGE KE.

[16]  C. Lemere,et al.  Novel Therapeutic Approach for the Treatment of Alzheimer's Disease by Peripheral Administration of Agents with an Affinity to β-Amyloid , 2003, The Journal of Neuroscience.

[17]  Jesús Avila,et al.  Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model. , 2003, Journal of Alzheimer's disease : JAD.

[18]  K. Duff,et al.  Cholesterol in Alzheimer's Disease and Tauopathy , 2002, Annals of the New York Academy of Sciences.

[19]  D. Westaway,et al.  Therapeutically effective antibodies against amyloid-β peptide target amyloid-β residues 4–10 and inhibit cytotoxicity and fibrillogenesis , 2002, Nature Medicine.

[20]  Yoo-Hun Suh,et al.  Amyloid Precursor Protein, Presenilins, and α-Synuclein: Molecular Pathogenesis and Pharmacological Applications in Alzheimer's Disease , 2002, Pharmacological Reviews.

[21]  M. Mullan,et al.  p35/Cdk5 pathway mediates soluble amyloid‐β peptide‐induced tau phosphorylation in vitro , 2002, Journal of neuroscience research.

[22]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[23]  E. Godaux,et al.  Neuronal Deficiency of Presenilin 1 Inhibits Amyloid Plaque Formation and Corrects Hippocampal Long-Term Potentiation But Not a Cognitive Defect of Amyloid Precursor Protein [V717I] Transgenic Mice , 2002, The Journal of Neuroscience.

[24]  P. Seymour,et al.  Tau protein phosphorylation as a therapeutic target in Alzheimer's disease. , 2002, Current topics in medicinal chemistry.

[25]  G. Cole,et al.  The Curry Spice Curcumin Reduces Oxidative Damage and Amyloid Pathology in an Alzheimer Transgenic Mouse , 2001, The Journal of Neuroscience.

[26]  B. Lamb,et al.  Transgenic mouse models of Alzheimer's disease. , 2001, Trends in genetics : TIG.

[27]  M. Mercken,et al.  A Cholesterol-Lowering Drug Reduces β-Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease , 2001, Neurobiology of Disease.

[28]  C. Link,et al.  Transgenic invertebrate models of age-associated neurodegenerative diseases , 2001, Mechanisms of Ageing and Development.

[29]  E. Kandel,et al.  APP Processing and Synaptic Plasticity in Presenilin-1 Conditional Knockout Mice , 2001, Neuron.

[30]  R. Nitsch,et al.  Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils , 2001, Science.

[31]  J. Hardy,et al.  Enhanced Neurofibrillary Degeneration in Transgenic Mice Expressing Mutant Tau and APP , 2001, Science.

[32]  D. Westaway,et al.  Transgenic mouse models of Alzheimer's disease , 2001, Physiology & Behavior.

[33]  David J. Cummins,et al.  Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[34]  Jürgen Götz,et al.  Tau and transgenic animal models , 2001, Brain Research Reviews.

[35]  S. Turner,et al.  Early-onset Amyloid Deposition and Cognitive Deficits in Transgenic Mice Expressing a Double Mutant Form of Amyloid Precursor Protein 695* , 2001, The Journal of Biological Chemistry.

[36]  I. Kola,et al.  BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. , 2001, Human molecular genetics.

[37]  M. Wolfe.  Presenilin and γ‐secretase: structure meets function , 2001 .

[38]  F. D. Miller,et al.  Functional gamma‐secretase inhibitors reduce beta‐amyloid peptide levels in brain , 2000, Journal of neurochemistry.

[39]  Ralph A. Nixon,et al.  Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease , 2000, Nature.

[40]  H Jick,et al.  Statins and the risk of dementia , 2000, The Lancet.

[41]  D. Selkoe.  The genetics and molecular pathology of Alzheimer's disease: roles of amyloid and the presenilins. , 2000, Neurologic clinics.

[42]  G. Celesia,et al.  Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. , 2000, Archives of neurology.

[43]  R. Motter,et al.  Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease , 2000, Nature Medicine.

[44]  Wen-Lang Lin,et al.  Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein , 2000, Nature Genetics.

[45]  K. Ashe,et al.  Ibuprofen Suppresses Plaque Pathology and Inflammation in a Mouse Model for Alzheimer's Disease , 2000, The Journal of Neuroscience.

[46]  M. Goedert,et al.  Tau mutations in frontotemporal dementia FTDP-17 and their relevance for Alzheimer's disease. , 2000, Biochimica et biophysica acta.

[47]  R. A. Crowther,et al.  Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein , 2000, Acta Neuropathologica.

[48]  A. Fagan,et al.  Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[49]  H. Geerts,et al.  Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein. , 1999, The American journal of pathology.

[50]  P. Wesseling,et al.  Agrin is a major heparan sulfate proteoglycan accumulating in Alzheimer's disease brain. , 1999, The American journal of pathology.

[51]  H. Meziane,et al.  Behavioral disturbances in transgenic mice overexpressing the V717F beta-amyloid precursor protein. , 1999, Behavioral neuroscience.

[52]  T. Hortobágyi,et al.  Neuroprotective approaches in experimental models of β-Amyloid neurotoxicity: Relevance to Alzheimer's disease , 1999, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[53]  S. Wagner,et al.  Amyloid production and deposition in mutant amyloid precursor protein and presenilin-1 yeast artificial chromosome transgenic mice , 1999, Nature Neuroscience.

[54]  R. Motter,et al.  Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse , 1999, Nature.

[55]  D. Selkoe,et al.  Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ-secretase activity , 1999, Nature.

[56]  Miles W. Miller,et al.  Increased vulnerability of hippocampal neurons to excitotoxic necrosis in presenilin-1 mutant knock-in mice , 1999, Nature Medicine.

[57]  B. Sommer,et al.  Neuron loss in APP transgenic mice , 1998, Nature.

[58]  S. W. Davies,et al.  Filamentous nerve cell inclusions in neurodegenerative diseases , 1998, Current Opinion in Neurobiology.

[59]  N. Maeda,et al.  Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse Apoe with human Apoe*2. , 1998, The Journal of clinical investigation.

[60]  J. Hardy,et al.  Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes , 1998, Nature Medicine.

[61]  B. Sommer,et al.  Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[62]  S. Paul,et al.  Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition , 1997, Nature Genetics.

[63]  B. Hyman,et al.  Aβ Deposition Is Associated with Neuropil Changes, but not with Overt Neuronal Loss in the Human Amyloid Precursor Protein V717F (PDAPP) Transgenic Mouse , 1997, The Journal of Neuroscience.

[64]  B. Hyman,et al.  APPSW Transgenic Mice Develop Age‐related Aβ Deposits and Neuropil Abnormalities, but no Neuronal Loss in CA1 , 1997, Journal of neuropathology and experimental neurology.

[65]  N. Maeda,et al.  Targeted Replacement of the Mouse Apolipoprotein E Gene with the Common Human APOE3 Allele Enhances Diet-induced Hypercholesterolemia and Atherosclerosis* , 1997, The Journal of Biological Chemistry.

[66]  S. Tonegawa,et al.  Skeletal and CNS Defects in Presenilin-1-Deficient Mice , 1997, Cell.

[67]  D. Price,et al.  Presenilin 1 is required for Notch 1 and Dll1 expression in the paraxial mesoderm , 1997, Nature.

[68]  M. Billingsley,et al.  Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration. , 1997, The Biochemical journal.

[69]  Richard Hollister,et al.  Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease , 1997, Annals of neurology.

[70]  R. Terry.  The pathology of Alzheimer's disease: Numbers count , 1997, Annals of neurology.

[71]  J. Hardy,et al.  Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1 , 1996, Nature.

[72]  S. Younkin,et al.  Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice , 1996, Science.

[73]  D. Selkoe,et al.  The Swedish mutation causes early-onset Alzheimer's disease by β-secretase cleavage within the secretory pathway , 1995, Nature Medicine.

[74]  M. Goedert,et al.  Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform. , 1995, The EMBO journal.

[75]  L. Mucke,et al.  Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein , 1995, Nature.

[76]  A. M. Saunders,et al.  Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease , 1994, Nature Genetics.

[77]  J. Hardy,et al.  Genetic Variability and Alzheimer’s Disease , 1994 .

[78]  D. Price,et al.  Cellular and molecular biology of Alzheimer's disease and animal models. , 1994, Annual review of medicine.

[79]  J. Growdon,et al.  Activation of protein kinase C inhibits cellular production of the amyloid beta-protein. , 1993, The Journal of biological chemistry.

[80]  J. Haines,et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.

[81]  J. Growdon,et al.  Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. , 1992, Science.

[82]  J. Hardy,et al.  Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.

[83]  M. Pericak-Vance,et al.  Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease , 1991, Nature.

[84]  R. Mahley,et al.  Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms. , 1981, The Journal of biological chemistry.